- Home
- NEWP vs PGEN Comparison
NEWP vs PGEN Comparison
Compare NEWP & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- PGEN
- Stock Information
- Founded
- NEWP 1972
- PGEN 1998
- Country
- NEWP Canada
- PGEN United States
- Employees
- NEWP N/A
- PGEN N/A
- Industry
- NEWP
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NEWP
- PGEN Health Care
- Exchange
- NEWP Nasdaq
- PGEN Nasdaq
- Market Cap
- NEWP 262.4M
- PGEN 292.6M
- IPO Year
- NEWP N/A
- PGEN N/A
- Fundamental
- Price
- NEWP $1.33
- PGEN $0.72
- Analyst Decision
- NEWP Strong Buy
- PGEN Buy
- Analyst Count
- NEWP 1
- PGEN 5
- Target Price
- NEWP $5.00
- PGEN $7.00
- AVG Volume (30 Days)
- NEWP 223.0K
- PGEN 930.3K
- Earning Date
- NEWP 02-11-2025
- PGEN 11-14-2024
- Dividend Yield
- NEWP N/A
- PGEN N/A
- EPS Growth
- NEWP N/A
- PGEN N/A
- EPS
- NEWP N/A
- PGEN N/A
- Revenue
- NEWP N/A
- PGEN $3,963,000.00
- Revenue This Year
- NEWP N/A
- PGEN N/A
- Revenue Next Year
- NEWP N/A
- PGEN $426.76
- P/E Ratio
- NEWP N/A
- PGEN N/A
- Revenue Growth
- NEWP N/A
- PGEN N/A
- 52 Week Low
- NEWP $0.87
- PGEN $0.65
- 52 Week High
- NEWP $2.53
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- NEWP 36.65
- PGEN 36.02
- Support Level
- NEWP $1.34
- PGEN $0.76
- Resistance Level
- NEWP $1.60
- PGEN $0.83
- Average True Range (ATR)
- NEWP 0.08
- PGEN 0.05
- MACD
- NEWP -0.02
- PGEN -0.01
- Stochastic Oscillator
- NEWP 11.17
- PGEN 16.55
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.